Lead Optimization and Preclinical Validation

Preclinical validation is where bold ideas meet rigorous testing. LIDE helps drug developers de-risk their programs by combining classical gold-standards with innovative models, and translational insight into a streamlined pathway designed for clinical success.

Our Optimized Roadmap for Preclinical Success

Traditional approaches rely heavily on 2D cell lines or sequential CDX → PDX workflows, which can waste time and resources. LIDE offers a more efficient and effective alternative:

• Start with Conditionally Reprogrammed (CR) Cells: Patient-derived, heterogeneous cultures that more accurately reflect clinical tumors than immortalized cell lines.
• Functional Diagnosis with MiniPDX: Rapid 7-day functional assays to test indications, prioritize drug candidates, and reduce reliance on guesswork before committing to long-term studies.
• Go directly to PDX Studies: Leverage LIDE’s biobank of 2,300+ clinically annotated PDX models, including rare cancers, resistant tumors, and genetically diverse phenotypes.
• Biomarker Discovery & Patient Stratification: Access to fresh patient samples, integrated omics and functional readouts to define predictive biomarkers and shape smarter clinical trial recruitment strategies.

Screening with MiniPDX®

A cornerstone of our platform, MiniPDX® serves as a bridge between in-vitro and in-vivo assays, helping screen indications, models, or candidate compounds before more costly investments in complex in-vivo studies.